ERBB2 and breast cancer: In this real-world cohort of patients with HER2 + BC, treated with upfront surgery followed by adjuvant paclitaxel and trastuzumab, we observed a 3-year RFS rate of 97.3% and 3-year DRFS rate of 98.2%.